Potassium Citrate

Constipation, Uremia, Kidney Stones + 10 more

Treatment

7 FDA approvals

20 Active Studies for Potassium Citrate

What is Potassium Citrate

Potassium citrate

The Generic name of this drug

Treatment Summary

Potassium citrate, or tripotassium citrate, is a white, odorless powder with a salty taste. It contains 38.3% potassium by weight and becomes very moist when exposed to air. Potassium citrate is used to treat kidney stones caused by renal tubular acidosis and hypocitraturic calcium oxalate nephrolithiasis.

Urocit-K

is the brand name

image of different drug pills on a surface

Potassium Citrate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Urocit-K

Potassium citrate

1985

60

Approved as Treatment by the FDA

Potassium citrate, otherwise called Urocit-K, is approved by the FDA for 7 uses like uric acid and Nephrolithiasis .

uric acid

Nephrolithiasis

Tubular Acidosis; Renal

Helps manage Tubular Acidosis; Renal

uric acid lithiasis

Helps manage uric acid lithiasis

NEPHROLITHIASIS, CALCIUM OXALATE

Helps manage Hypocitraturic calcium oxalate nephrolithiasis

Renal tubular acidosis

Helps manage Tubular Acidosis; Renal

Lithiasis

Helps manage uric acid lithiasis

Effectiveness

How Potassium Citrate Affects Patients

Potassium citrate affects the urine in a way that helps prevent crystals and stones from forming in the kidneys. It increases the citrate levels in the urine to make it harder for salts like calcium oxalate, calcium phosphate, and uric acid to form crystals. It also stops crystals from forming on their own.

How Potassium Citrate works in the body

After taking potassium citrate, it is broken down in the body and produces an alkaline load. Potassium citrate increases the amount of citrate in the urine, as well as its pH level. Potassium citrate also increases the amount of potassium in the urine, but can also cause a temporary decrease in calcium levels.

When to interrupt dosage

The suggested measure of Potassium Citrate is contingent upon the acknowledged disorder, including Metabolic Acidosis, laxative and Renal tubular acidosis. The quantity of dosage is outlined in the table beneath, reliant upon the method of delivery (e.g. Solution - Oral or Liquid).

Condition

Dosage

Administration

Metabolic acidosis

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

Uremia

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

Constipation

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

Renal tubular acidosis

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

Bowel preparation therapy

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

Kidney Stones

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

Lithiasis

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

NEPHROLITHIASIS, CALCIUM OXALATE

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

Gout Flares

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

Nephrolithiasis

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

Acidosis

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

uric acid

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

laxative

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

Warnings

Potassium Citrate Contraindications

Condition

Risk Level

Notes

Hyperkalemia

Do Not Combine

Renal Insufficiency

Do Not Combine

Urinary tract infection

Do Not Combine

Gastrointestinal tract structure

Do Not Combine

Peptic Ulcer Disease

Do Not Combine

There are 20 known major drug interactions with Potassium Citrate.

Common Potassium Citrate Drug Interactions

Drug Name

Risk Level

Description

2,5-Dimethoxy-4-ethylamphetamine

Major

The excretion of 2,5-Dimethoxy-4-ethylamphetamine can be decreased when combined with Potassium citrate.

2,5-Dimethoxy-4-ethylthioamphetamine

Major

The excretion of 2,5-Dimethoxy-4-ethylthioamphetamine can be decreased when combined with Potassium citrate.

4-Bromo-2,5-dimethoxyamphetamine

Major

The excretion of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when combined with Potassium citrate.

Albutrepenonacog alfa

Major

The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Potassium citrate.

Amiloride

Major

The risk or severity of hyperkalemia can be increased when Potassium citrate is combined with Amiloride.

Potassium Citrate Toxicity & Overdose Risk

The toxic dose of this drug in dogs is 176 mg/kg when given intravenously.

image of a doctor in a lab doing drug, clinical research

Potassium Citrate Novel Uses: Which Conditions Have a Clinical Trial Featuring Potassium Citrate?

74 ongoing trials are assessing the capacity of Potassium Citrate to provide Bowel preparation therapy, Kidney Stones and Chronic Constipation relief.

Condition

Clinical Trials

Trial Phases

Kidney Stones

32 Actively Recruiting

Not Applicable, Early Phase 1, Phase 2

Constipation

18 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 3, Phase 1

Bowel preparation therapy

1 Actively Recruiting

Phase 1, Phase 2

Metabolic acidosis

0 Actively Recruiting

NEPHROLITHIASIS, CALCIUM OXALATE

3 Actively Recruiting

Not Applicable

Gout Flares

1 Actively Recruiting

Phase 2

Nephrolithiasis

0 Actively Recruiting

Lithiasis

0 Actively Recruiting

uric acid

0 Actively Recruiting

Acidosis

0 Actively Recruiting

Uremia

0 Actively Recruiting

Renal tubular acidosis

0 Actively Recruiting

laxative

0 Actively Recruiting

Potassium Citrate Reviews: What are patients saying about Potassium Citrate?

5

Patient Review

3/28/2013

Potassium Citrate for Calcium Oxalate Kidney Stones

I was having to go through kidney stone surgery multiple times per year, but since I started taking this medication, I haven't had a single operation in 18 months. It has caused irregular heart beat but a heart pill is reducing that.

5

Patient Review

9/18/2016

Potassium Citrate for High Amount of Oxalic Acid in the Urine

This medication is great for me, given that I was born with bad kidneys. I have experienced no negative side effects and my kidney count has been stable for 8 years.

5

Patient Review

3/23/2022

Potassium Citrate for Prevention of Calcium-Containing Kidney Stones

I had two operations for kidney stones, which caused my kidneys to swell up. Since then, I've passed a kidney stone every year or so. However, since I started taking this medication, I've only passed one stone. And weirdly enough, I also started losing weight without even dieting! I went from a size 18 to a size 14 in just three months. Clearly my body needed some potassium! At first I felt a little strange taking the medication, but after a few weeks I felt perfectly normal again.

5

Patient Review

10/8/2013

Potassium Citrate for Calcium Oxalate Kidney Stones

After a few weeks of mild stomach discomfort, this drug really helped to shrink my stones and I haven't had any growth in over two years!

5

Patient Review

7/28/2016

Potassium Citrate for Uric Acid Kidney Stones

I had 25 stones and many ER visits and surgical procedures. Since starting this drug over 1 1/2 years ago, no more stones....so happy...

4.3

Patient Review

1/27/2017

Potassium Citrate for Prevention of Calcium-Containing Kidney Stones

I've been using this medication to prevent kidney stones and it has been working great for me.

3.7

Patient Review

9/10/2011

Potassium Citrate for Uric Acid Kidney Stones

I've been on this medication for over 20 years, and I feel like I've had more stones than ever before. It seems like drug companies are just trying to make more money these days.

3.7

Patient Review

5/14/2018

Potassium Citrate for Calcium Oxalate Kidney Stones

While I haven't had any stones since starting this medication, I have felt very tired, my heartbeat has been irregular, and I've been dizzy. These effects are not pleasant, so I reduced my dosage from 3 pills per day to just 1. Unfortunately, the effects remain. Not sure what to do next.

3.7

Patient Review

6/13/2013

Potassium Citrate for Calcium Oxalate Kidney Stones

The medication itself is fine, but the price increase is outrageous. I was paying $8 per month and now it's jumped to $120. There has to be a more affordable option out there for people like me.

3.7

Patient Review

12/25/2010

Potassium Citrate for Calcium Oxalate Kidney Stones

3.3

Patient Review

9/30/2018

Potassium Citrate for Calcium Oxalate Kidney Stones

I've only been on the medication for two days, but I am already experiencing extreme tingling and pain in my feet and hands. I'm hoping this will improve with time, as I don't want to deal with kidney stones.

3

Patient Review

1/31/2013

Potassium Citrate for Calcium Oxalate Kidney Stones

I've had kidney stones for a while now, and I'm not sure how well this treatment is working. I sometimes see the casing in my stool, but I wonder if it is really effective.

2.7

Patient Review

8/1/2012

Potassium Citrate for Prevention of Calcium-Containing Kidney Stones

I first took this medicine 40 years ago and thought it had disappeared from the chemist. Then I rediscovered it a couple of years ago and it is a life saver in emergencys.

2.3

Patient Review

11/1/2015

Potassium Citrate for Uric Acid Kidney Stones

My blood pressure has fallen so low that I have no energy. This happened over the course of 1 month, but less than 2 months. I am stopping this drug before it kills me.

2.3

Patient Review

12/3/2016

Potassium Citrate for Uric Acid Kidney Stones

I increased my dosage from one pill per day to six, and now I'm experiencing dry mouth and a general sense of malaise.

2.3

Patient Review

3/25/2016

Potassium Citrate for Uric Acid Kidney Stones

The stomach upset caused by this medication is really bad. I don't know if I can continue taking it.

1

Patient Review

3/7/2011

Potassium Citrate for Uric Acid Kidney Stones

This drug definitely helps to reduce the number of kidney stones I get; however, you have to be really careful about following the directions.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about potassium citrate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of taking potassium citrate?

"If you experience any of the following serious side effects while taking this medication, you should tell your doctor right away:

-Muscle cramps or weakness

-Severe dizziness

-Slow or irregular heartbeat

-Mental/mood changes (such as confusion or restlessness)

-Tingling of the hands or feet

-Unusually cold skin"

Answered by AI

Is potassium citrate good for health?

"Potassium citrate is a compound consisting of potassium and citric acid, often used as a food additive. Its health benefits include aiding heart and bone health, as well as helping with conditions like kidney stones."

Answered by AI

What is potassium citrate used for?

"Potassium citrate is used to treat a kidney stone condition called renal tubular acidosis. It is also used to prevent kidney stones from forming in people who have gout. Potassium citrate works by making urine more alkaline, which helps to prevent kidney stones from forming."

Answered by AI

Can I take potassium citrate every day?

"Adults should start by taking 15 to 30 milliequivalents (mEq) of the medication two times a day, or 10 to 20 mEq three times a day. The doctor may increase the dose as needed, but the dose usually should not exceed 100 mEq per day. Children's dosages must be determined by a doctor."

Answered by AI

Clinical Trials for Potassium Citrate

Image of University of Michigan in Ann Arbor, United States.

Stent Omission vs Placement for Kidney Stones

18+
All Sexes
Ann Arbor, MI

The study is being completed to compare patient reported outcomes for stent omission vs. placement after using a ureteral access sheath for uncomplicated ureteroscopy. Participants that consent for the study will complete baseline PRO questionnaires. A UAS will be used during surgery, and the size left to the discretion of the surgeon. At the end of the procedure, the urologist will evaluate the ureter for iatrogenic injury, and the ureter will be graded using the Post Ureteroscopic Lesion Scale (PULS). Patients assessed with PULS 0 and PULS 1 will meet 2nd stage eligibility and will be randomized 1:1 to either stent omission or stent placement. When a stent is placed, the stent type and decision to leave a string (tether) will be at the operating urologist's discretion. Hypothesis: \- stent omission arm will be non-inferior to stent placement in Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference and Pain Intensity, and have lower 30-day healthcare utilization.

Recruiting
Has No Placebo

University of Michigan

Khurshid Ghani, MD

Have you considered Potassium Citrate clinical trials?

We made a collection of clinical trials featuring Potassium Citrate, we think they might fit your search criteria.
Go to Trials
Image of United States, Alabama University of Alabama at Birmingham in Birmingham, United States.

Oxalate Synthesis for Kidney Stones

18 - 80
All Sexes
Birmingham, AL

The goal of this clinical trial study is to test if patients with idiopathic calcium oxalate kidney stones have an increased production of oxalate by the body, which would lead to increased urinary excretion of oxalate. The study will recruit adult patients with a history of calcium oxalate kidney stones and healthy volunteers without kidney stones. Participants will ingest fixed diets containing low amounts of oxalate for 5 days ingest a soluble form of glycolate and vitamin C collect urine, blood, stool during the dietary and oral dosing portions of the study and also collect breath sample during the oral glycolate test

Recruiting
Has No Placebo

United States, Alabama University of Alabama at Birmingham (+1 Sites)

Sonia Fargue, PhD

Have you considered Potassium Citrate clinical trials?

We made a collection of clinical trials featuring Potassium Citrate, we think they might fit your search criteria.
Go to Trials
Image of Hamilton Health Sciences in Hamilton, Canada.

Kiwifruit Extract for Constipation in Children

4 - 17
All Sexes
Hamilton, Canada

The goal of this pilot feasibility randomized controlled trial is to determine whether Actazin (kiwifruit extract) is a feasible and effective alternative to polyethylene glycol 3350 (PEG 3350) for maintenance therapy in children with functional constipation (FC). This study will include children aged 4 to 17 years who meet the Rome IV criteria for functional constipation. The main questions it aims to answer are: 1. Is it feasible to conduct a definitive, multi-centre trial comparing Actazin to PEG 3350 in children with FC? 2. What are the within-group differences in clinical outcomes such as stool frequency, abdominal pain, and laxative use over a 4-week period? Researchers will compare chewable Actazin tablets with placebo PEG 3350 powder to PEG 3350 powder with placebo Actazin tablets to see if Actazin is a viable non-pharmacologic natural health product alternative for treating FC. Participants will: Undergo an initial bowel cleanout using PEG 3350 and bisacodyl. Following, they will be randomized to one of two groups: 1. Actazin chewable tablets (titrate to effect: 600-2400 mg/day) + placebo PEG 3350 2. PEG 3350 (dose based on age and titratable to effect) + placebo Actazin chewable tablets Participants will take the assigned intervention daily for 4 weeks and complete a daily bowel diary recording stool frequency, consistency (Bristol Stool Scale), abdominal pain, and laxative use. They will have weekly follow-ups via phone or electronic survey to assess adherence, medication use, and adverse events. Additionally, a bi-weekly follow-up will be conducted for an additional 8 weeks to track longer-term outcomes. Outcomes: Primary feasibility outcomes include consent rate, adherence to allocated intervention, and 4-week follow-up completion rate. Secondary clinical outcomes include resolution of FC (Rome IV criteria), weekly stool frequency, abdominal pain episodes, use of rescue laxatives, and treatment palatability. This study is being conducted at McMaster Children's Hospital and is funded by the Hamilton Academic Health Sciences Organization (HAHSO). Data collection will be managed using the Lumedi™ platform, and safety will be overseen by a Data Safety Monitoring Board (DSMB).

Phase 2 & 3
Waitlist Available

Hamilton Health Sciences

Elyanne Ratcliffe, MD

Image of University of Alberta in Edmonton, Canada.

Pelvic Health Rehabilitation for Breast and Gynecologic Cancer

18+
Female
Edmonton, Canada

The GYVE study aims at testing an online program (eModule) to help people who have had breast or gynecologic cancer and are experiencing pelvic health issues like urinary incontinence and pain during sex. These cancers and their treatments can cause significant pelvic health problems, affecting daily life and quality of life. Physiotherapy can help, but access is often limited due to costs and other barriers. The study will involve 20 participants from Quebec and Edmonton, who will take part in a 12-week program with weekly online group sessions led by a physiotherapist. Topics include pelvic floor muscle training, use of vaginal moisturizers, hydration, diet, and pain management. Led by experts in cancer rehabilitation and pelvic health, the study aims to provide valuable information on the feasibility and effectiveness of the eModule, potentially leading to broader implementation to help more people with lived experience of cancer.

Recruiting
Has No Placebo

University of Alberta (+1 Sites)

Have you considered Potassium Citrate clinical trials?

We made a collection of clinical trials featuring Potassium Citrate, we think they might fit your search criteria.
Go to Trials